Peppermint Venture Partners and Goodvent led a €2.6m investment round for Emperra E-Health Technologies, whose core product is a GSM and web-based telemedical management system for patients with insulin dependent diabetes.
Existing investors BC Brandenburg Capital and MBG also participated in the round.
The company’s Esysta technology allows the complete capture of all relevant data such as insulin doses, blood sugar levels and carbohydrates. According to the company, it significantly improves diagnostics, therapy, patient management, patient compliance, self-empowerment and quality of life, resulting in cost reductions for insurance companies.
BC Brandenburg Capital senior fund manager Thomas Krause said, “We have supported this company since the product development stage.
“The involvement of new investors confirms our commitment to date. Special thanks are due to the Emperra management for their consistent application of the growth strategy.”
Peppermint, which is based in Berlin, invests in healthcare startups focused on medical devices that have already shown a proof of concept. The investment was made from its Peppermint Charité Biomedical Fund launched in 2010 in partnership with the Charité Foundation.
Earlier this year the firm backed biotech business CryoTherapeutics by participating in its €3m Series A funding round.
Copyright © 2013 AltAssets